<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099944</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2305</org_study_id>
    <nct_id>NCT00099944</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes</brief_title>
  <official_title>Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a
      single oral drug. The purpose of this study is to assess the safety and effectiveness of two
      doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when
      added to glimepiride in people with type 2 diabetes not at target blood glucose levels on a
      sulfonylurea alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c after 24 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose at 24 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with endpoint HbA1c &lt;7% after 24 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with reduction in HbA1c &gt;/=to 0.7% after 24 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile after 24 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs. low baseline HbA1c</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LAF237 50 mg qd + glimepiride 4 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LAF237 50 mg qd + glimepiride 4 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAF237 50 mg bid + glimepiride 4 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LAF237 50 mg bid + glimepiride 4 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAF237 placebo + glimepiride 4 mg qd</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LAF237 placebo + glimepiride 4 mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <arm_group_label>LAF237 50 mg qd + glimepiride 4 mg qd</arm_group_label>
    <arm_group_label>LAF237 50 mg bid + glimepiride 4 mg qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride 4 mg qd</description>
    <arm_group_label>LAF237 50 mg qd + glimepiride 4 mg qd</arm_group_label>
    <arm_group_label>LAF237 50 mg bid + glimepiride 4 mg qd</arm_group_label>
    <arm_group_label>LAF237 placebo + glimepiride 4 mg qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAF237 placebo</intervention_name>
    <arm_group_label>LAF237 placebo + glimepiride 4 mg qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood glucose criteria must be met

          -  Previously treated with a sulfonylurea for at least 3 months

          -  Body mass index (BMI) in the range 22-45

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Pregnancy or lactation

          -  Evidence of serious cardiovascular complications

          -  Evidence of serious diabetic complications

          -  Laboratory value abnormalities as defined by the protocol

          -  Known sensitivity to glimepiride

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2004</study_first_submitted>
  <study_first_submitted_qc>December 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2004</study_first_posted>
  <last_update_submitted>May 3, 2012</last_update_submitted>
  <last_update_submitted_qc>May 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>vildagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

